Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk ...

The update includes new focus on monitoring asthma control as the goal for asthma therapy and distinguishing between classifying asthma severity and monitoring asthma control Emphasis is placed on ...

In a recent study published in the Respiratory Research journal, researchers in Hong Kong assessed the deterioration of asthma control in patients recovering from mild to moderate coronavirus disease ...

To claim CE credit for this activity, please visit https://www.pharmacytimes.org/courses/emerging-care-management-strategies-for-severe-asthma-integrating-biologic ...